Frontage is a reliable provider of early-stage screening services for drug-drug interactions (DDI)

DDI are critical safety concerns in preclinical and clinical development by the regulatory agencies. Therefore early-stage screening of compounds for potential DDI using in vitro techniques becomes indispensable to reduce late-stage compound attrition.

The Cytochrome P450 enzymes play a major role in the metabolism of drugs. A change in their activity, either by inhibition or induction, may have significant effects on the pharmacokinetics and therefore on the pharmacologic effects of the compounds, which makes them an important target for assessing drug-drug interactions.

While inhibition of CYP enzymes responsible for the metabolism of a co-medicated drug may raise its concentration to a toxic level, induction of CYP may hasten the elimination of the co-medicated drug to sub-therapeutic levels leading to a dramatic decrease in its pharmacological response.

CYP Interaction Services at Frontage:

• CYP Inhibition Assays
• CYP Ki Determinations
• CYP TDI – IC50 Shift
• CYP TDI/MBI Kinact/Ki
• CYP Induction